📣 Paper of the day
Prashant Nasa
ICU Physician - Co-editor: Rational use of IV Fluids in Critically ill - PROVE Network - Delphi Methodology - Fluid and Oxygen are Drugs - X: @drnasap
Published in JAMA
Early and Empirical High-Dose Cryoprecipitate for Hemorrhage After Traumatic Injury. The CRYOSTAT-2 Randomized Clinical Trial
The CRYOSTAT-2 trial investigated the effectiveness of early and empirical high-dose cryoprecipitate transfusion in addition to standard care in patients with trauma and bleeding. The primary outcome was all-cause mortality at 28 days. .
🔑 takeaways:
1️⃣ The addition of early and empirical high-dose cryoprecipitate to standard care did not improve survival outcomes in patients with trauma and bleeding.
2️⃣ There were also no differences in safety outcomes, transfusion requirements, or incidence of thrombotic events.
Limitations:
1. The trial did not find any significant benefit of early and empirical high-dose cryoprecipitate transfusion, but further research may be needed to determine if there are specific subgroups of patients who could potentially benefit from this intervention.
2. While cryoprecipitate is a standard care for fibrinogen replacement, alternative interventions or strategies may be explored to improve outcomes in patients with trauma and bleeding.
FEA Medicina Intensiva.
1yGood morning, what differences and advantages does cryoprecipitate have compared to the prothrombotic complex? At my hospital we don't have cryoprecipitate, that's why I'm asking. Good morning.